{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '27', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Study Governance Committees:', 'Steering Committee', 'Yes', 'Executive Oversight Committee', 'Yes', 'Data Monitoring Committee', 'Yes', 'Clinical Adjudication Committee', 'No', 'Study governance considerations are outlined in Appendix 1.', 'Study Accepts Healthy Volunteers: No', 'A list of abbreviations used in this document can be found in Appendix 8.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '28', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '1.2', 'Schema', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo and the Second-course Treatment Phase have been', 'removed from the study. The original study design and updates to this design as of Amendment 007-06 (indicated by', 'strikethrough) are depicted in Figure 1.', 'Figure 1', 'Original and Updated Study Design: Initial Treatment Phase', 'Key Inclusion/Exclusion:', 'Pembrolizumab 200 mg IV Q3W', 'tenvatinib-20-mg-Po-ee-', 'tenvatinib-20-mg-Po-Qe-', 'Safety', 'Follow-', 'Survival', 'Stage IV NSCLC', 'Follow-Up', 'Up', 'Follow-Up', 'Rand', 'Up to 35 cycles or meeting DC*', 'Cycle 36 until meeting DC', 'No prior systemic treatment for stage', 'IV disease', '1:1', 'N=620', 'Post-treatment Phase', 'TPS >1%', 'Measurable disease', 'Pembrolizumab 200 mg IV Q3W', 'Matehing-PlaeebePo-Q-', 'Matching Placebe POQQ', 'Safely', 'Follow-', 'Survival', 'ECOG PS0-1', 'Follow-Up', 'Up', 'Follow-Up', 'EGFR/ALKIROS1 therapy is not', 'Up to 35 cycles or meeting DC', 'Cycle 36 until meeting 9C', 'indicated', 'Stratificationfactors:', '1. Geography Site (East Asian vs Non-East Asian)', '2. ECOG PS (0vs1)', '3. TPS (1%-49% vs >50%)', 'Abbreviations: ALK = ALK receptor tyrosine kinase; DC = discontinuation; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EGFR', '= epidermal growth factor receptor; IV = intravenous; NSCLC = non-small cell lung cancer; PD = progressive disease; PO = orally; Q3W = every 3 weeks;', 'QD = once daily; ROSI = ROS proto-oncogene 1; TPS = tumor proportion score.', '* DC criteria are listed in Section 7.1.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '29', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '1.3', 'Schedule of Activities (SoA)', '1.3.1', 'Initial Treatment Phase', 'NOTE:', 'As of Amendment 007-06, lenvatinib and matching placebo have been removed from the study. Participants who', 'remain on treatment will receive open-label pembrolizumab monotherapy as per protocol. Administration', 'of', 'lenvatinib', 'and', 'placebo, collection of ePRO data, and collection of most of the blood biomarkers have been removed from the SoA. Other', 'study procedures specific to lenvatinib/matching have also been removed.', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', 'Every', '-28 to -1', '5', '6 to 35', 'Every', 'Visit Timing/', '1', '2', '3', '4', 'post last', 'administration unless', 'DC', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(+3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '+3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Administrative and General Procedures', 'ICF must be signed', 'before any protocol-', 'specific screening', 'Informed consent', 'X', 'procedures are', 'performed. Additional', 'consent is required at', 'PD.', 'Inclusion/exclusion', 'X', 'criteria', 'Participant', 'X', 'identification card', 'Update at C1D1.', 'Demographic and', 'X', 'medical history', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']\n\n###\n\n", "completion": "END"}